Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 232-190-8 | CAS number: 7789-79-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From May 21 to Agust 20, 2013
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 013
- Report date:
- 2013
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.1 tris (Acute Oral Toxicity - Acute Toxic Class Method)
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- no
Test material
- Reference substance name:
- Calcium phosphinate
- EC Number:
- 232-190-8
- EC Name:
- Calcium phosphinate
- Cas Number:
- 7789-79-9
- Molecular formula:
- Ca.2H3O2P
- IUPAC Name:
- calcium phosphinate
- Test material form:
- solid: particulate/powder
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- Species and strain: Rat, Crl: CD (SD) Sprague Dawley
Sex: Females (nulliparous and non-pregnant)
Age and weight range: 6 to 7 weeks old, 150 to 174 grams (at order)
Supplier: Charles River Italia S.p.A., Calco (Lecco), Italy
Breeder: Charles River Italia S.p.A., Calco (Lecco), Italy
Date of arrival: 16 May and 18 July 2013
Acclimatisation period: At least 5 days
Veterinary health check: After arrival
No. of animals/cage: 3 during the study; up to 5 during acclimatisation
Housing: Solid bottomed cages measuring 59.5x38x20 cm, with nesting material provided into suitable bedding bags.
Cage control: Daily inspected and changed as necessary (at least 2 times/week)
Water: Drinking water supplied to each cage via a water bottle
Water supply: Ad libitum
Diet: 4 RF 18 (Mucedola S.r.l., Via G. Galilei, 4, 20019, Settimo Milanese (MI) Italy)
Diet supply: Ad libitum throughout the study except for dosing procedure
Room lighting : Artificial (fluorescent tubes), daily light/dark cycle of 12/12 hours
Air changes: Approximately 15 to 20 air changes per hour
Temperature range: 22 °C ± 2 °C
Relative humidity range: 55 % ± 15 %
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- Frequency of treatment: Once only, on the day of dosing (Day 1).
Fasting procedure: Overnight prior to dosing (Day –1) up to 4 hours after dosing.
Dose calculation: Dose volume of 10 ml/kg of body weight for each animal.
Dosing method: By gavage, using a plastic feeding tube attached to a syringe of suitable capacity. - Doses:
- 300 mg/kg
2000mg/kg - No. of animals per sex per dose:
- 6 females
- Control animals:
- no
- Details on study design:
- A first sub-group of 3 female animals was dosed at a level of 300 mg/kg (Step 1). No mortality occurred. A second sub-group, similarly composed, was then dosed at the same dose level (Step 2). No mortality occurred. On the basis of these results and of the testing strategy indicated in the OECD 423, a further sub-group of 3 females was dosed at a dose level of 2000 mg/kg (Step 3). Mortality did not occur. A further sub-group was finally dosed at the same dose level (2000 mg/kg, Step 4). Two animals died following dosing.
No further doses were investigated since the objective of the study had been achieved. - Statistics:
- No statistic analysis necessary.
Results and discussion
Effect levelsopen allclose all
- Sex:
- female
- Dose descriptor:
- LD0
- Effect level:
- ca. 300 mg/kg bw
- Based on:
- test mat.
- Sex:
- female
- Dose descriptor:
- LD50
- Effect level:
- ca. 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- 0/3 + 0/3 at 300 mg/kg
0/3 + 2/3 at 2000 mg/kg - Clinical signs:
- other: Piloerection was observed approximately 2 and 4 hours after dosing in the animals initially dosed at 300 mg/kg (Step 1) and in the further 3 females dosed at the same dose level (300 mg/kg - Step 2). Recovery occurred by Day 2. No mortality occurred in th
- Gross pathology:
- The necropsy examination performed at the end of the observation period on all animals dosed at 300 mg/kg (Steps 1 and 2) did not reveal any external or internal alterations.
Necropsy examination performed in the early decedent females treated at 2000 mg/kg (Step 4) revealed red areas in the glandular region of the stomach in both animals. In addition, red colour of the glandular region/mucosa of the stomach, jejunum and caecum and mucoid material in the stomach and jejunum were observed in one of these early decedent females. The necropsy examination performed at the end of the observation period on surviving females dosed at 2000 mg/kg (Steps 3 and 4) did not reveal any external or internal alterations.
Applicant's summary and conclusion
- Interpretation of results:
- other: Category 4 (Harmful if swallowed) based on CLP Regulation (EC no. 1272/2008)
- Conclusions:
- The acute toxicity of Ca(H2PO2)2 was investigated following a single oral administration (10 ml/kg in purified water) to the Sprague Dawley rat followed by a 14-day observation period.
No mortality occurred and no significant clinical signs were observed in the 6 animals following dosing at 300 mg/kg.
Mortality occurred in 2/6 animals dosed at 2000 mg/kg within Day 3 of the study. Several clinical signs were observed after dose of 2000 mg/kg.
These results indicate that the test item Ca(H2PO2)2 induced effects of toxicological relevance (mortality) in the rat following oral administration of a single dose at 2000 mg/kg. No mortality or severe signs of toxicity were observed following dosing at 300 mg/kg. These results indicate the LD50 to be greater than 300 but lower than 2000 mg/kg body weight.
European Directives concerning the classification, packaging and labelling of dangerous substances (Council Regulation (EC) No. 1272/2008 and subsequent revisions) would indicate the following:
Classification : Category 4
Signal word : Warning
Hazard statement H302: Harmful if swallowed - Executive summary:
The acute toxicity of Ca(H2PO2)2 was investigated following a single oral administration to the Sprague Dawley rat followed by a 14-day observation period.
A first sub-group of 3 female animals was initially dosed at 300 mg/kg (Step 1). No mortality occurred. Clinical signs were limited to piloerection, observed on the day of dosing.
A second sub-group of 3 female animals was then dosed at the same dose level (Step 2). No deaths occurred. Piloerection was observed on the day of dosing.
A third sub-group was dosed at a higher dose level of 2000 mg/kg (Step 3). No deaths occurred. Clinical signs observed were reduced activity and semiclosed eyes. Recovery occurred by Day 3.
A fourth sub-group was finally dosed at 2000 mg/kg (Step 4). Two animals were found dead on Days 1 and 3 of the observation period. The following signs were noted after dosing: reduced activity, piloerection, hunched posture, semiclosed eyes, pallor and scab on the neck. Recovery occurred in the surviving animal by Day 4.
Body weight changes recorded during the observation period in the animals treated at 300 mg/kg were within the expected range for this strain and age of animals.
Body weight losses/reduced body weight gain were observed in the animals treated at 2000 mg/kg on Day 2 of the observation period. Changes in body weight observed at the end of the observation period in surviving females were within the expected range for this strain and age of animals.
No abnormalities were observed at necropsy examination performed on animals treated at 300 mg/kg at the end of the observation period.
Necropsy examination performed in the early decedent females treated at 2000 mg/kg revealed abnormal areas in the stomach of both animals. In addition, abnormal red colour of the stomach, jejunum and caecum and mucoid material in the stomach and jejunum were observed in one of these early decedent females. The necropsy examination performed at the end of the observation period on surviving females dosed at 2000 mg/kg did not reveal any external or internal alterations.
These results indicate that the test item Ca(H2PO2)2 induced effects of toxicological relevance (mortality) in the rat following oral administration of a single dose at 2000 mg/kg. No mortality or severe signs of toxicity were observed following dosing at 300 mg/kg. These results indicate the LD50 to be greater than 300 but lower than 2000 mg/kg body weight.
European Directives concerning the classification, packaging and labelling of dangerous substances (Council Regulation (EC) No. 1272/2008 and subsequent revisions) would indicate the following:
Classification: Category 4
Signal word: Warning
Hazard statement: H302: Harmful if swallowed
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.